Evidence map›Paper›PMID 36610206›Full record

Trial reportAsian journal of psychiatry2023

Real world research on transcranial magnetic stimulation treatment strategies for neuropsychiatric symptoms with long-COVID in Japan.

Yoshihiro Noda, Akiko Sato, Misaki Shichi, Ayano Sato, Kyoshiro Fujii, Mio Iwasa, Yasuhiro Nagano, Ryosuke Kitahata, Ryota Osawa

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Asian journal of psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06940609 (Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06940609 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)

TypeinterventionalSponsorUniversity of New MexicoRan2025 to 2029Enrolled60ConditionsLong COVID, Long COVID Syndrome, Long COVID-19 Syndrome, PASCArmsaccelerated intermittent theta burst stimulation
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Intervention modalities for brain fog caused by long-COVID: systematic review of the literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  3. A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yoshihiro NodaShinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. Electronic address: yoshi-tms@keio.jp.
Akiko SatoTokyo Yokohama TMS Clinic, Tokyo, Japan.
Misaki ShichiTokyo Yokohama TMS Clinic, Tokyo, Japan.
Ayano SatoTokyo Yokohama TMS Clinic, Tokyo, Japan.
Kyoshiro FujiiShinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan.
Mio IwasaShinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan.
Yasuhiro NaganoTokyo Yokohama TMS Clinic, Tokyo, Japan.
Ryosuke KitahataShinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan.
Ryota OsawaTokyo Yokohama TMS Clinic, Tokyo, Japan.
Sleep Comprehensive Care Clinic Yoyogi · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The number of patients suffering from long-COVID is currently increasing rapidly, even after the acute symptoms of COVID-19 have improved. The objective of this study was to investigate the effects of a pilot transcranial magnetic stimulation (TMS) treatment on neuropsychiatric symptoms caused by long-COVID. In this study, we examined the efficacy of the TMS treatment protocol, which has been established to be effective in refractory depression, by applying it to patients who sought TMS treatment for neuropsychiatric symptoms caused by long-COVID at TMS clinics in Tokyo, Japan in the context of the real world TMS registry study in Japan. Of the 23 patients (13 females) with long-COVID included in this case series, the main neuropsychiatric symptoms were chronic fatigue (n = 12) and cognitive dysfunction (n = 11), but most patients also showed mild depressive symptoms. The mean score on the Montgomery-Åsberg Depression Rating Scale before TMS treatment was 21.2, which improved to 9.8 after treatment. Similarly, the score on the Performance Status, which assesses the degree of fatigue, improved from 5.4 to 4.2, and the score on the Perceived Deficits Questionnaire-Depression 5-item, which reflects cognitive function, improved from 10.0 to 6.3. Although a few patients complained of pain at the stimulation site during the TMS as a side effect, there were no serious adverse events. Despite the limitations of this open-label pilot study, the TMS protocol implemented in this study may have beneficial effects on neuropsychiatric symptoms caused by long-COVID, including depressive symptoms, chronic fatigue, and cognitive impairment. These preliminary findings warrant further validation in randomized controlled trials.

Indexed as

COVID-19Fatigue Syndrome, ChronicMajor Depressive DisorderFemaleHumansJapanPilot ProjectsPost-Acute COVID-19 SyndromeTranscranial Magnetic StimulationTreatment OutcomeBrain fogChronic fatigueCognitive dysfunctionCOVID-19Long-COVIDTMS

Identifiers

PMID36610206
PMCPMC9795803
OpenAlexW4313546813

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.